HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies
New research partnerships with world-leading institutions University of Bern, University Hospital of Bern and Lausanne University Hospital Non-dilutive funding will enable the development of therapies targeting lncRNA for cardiomyopathy and squamous cell carcinoma LAUSANNE, Switzerland and SAN DIEGO – May 3, 2022 — HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding …